Apimeds Pharmaceuticals US Reports Third Quarter 2026 Results, Delivers First Operating Revenue from Technology Services
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Apimeds Pharmaceuticals US (APUS) reported third-quarter 2026 revenue of $2.89 million in its first full quarter of revenue from its technology business. Revenue was zero a year earlier. Operating income was $2.0 million, and net income of $33.6 million included a $25.26 million unrealized gain on digital assets. Apimeds completed its transition to technology infrastructure by disposing of its former biopharmaceutical subsidiary on July 14, 2026.
The nine-month net loss was $21.6 million. At September 30, 2026, Apimeds held $17,912 in cash and $8.0 million in restricted cash. Its senior secured convertible note matures December 8, 2026, with $10.5 million in outstanding principal. Digital assets represented 93% of total assets. These conditions raise substantial doubt about Apimeds’ ability to continue operating. The company is pursuing capital raising and refinancing alternatives.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointThird-quarter revenue reached $2.89 million versus no revenue a year earlier, marking the first full quarter of technology revenue
- Moderate pointThird-quarter operating income was $2.0 million
- Moderate pointThird-quarter net income was $33.6 million, or $19.13 per basic share and $7.68 per diluted share, including a $25.26 million unrealized digital-asset gain
- Moderate pointSubsidiary financing brought in $750,000 in October 2026 21% of market cap
- Moderate pointTechnology business transition was completed with the July 14, 2026 disposal of the former biopharmaceutical subsidiary
- Moderate pointBlockAssure agreement gives MindWave a two-year insurance infrastructure contract signed October 4, 2026
- Moderate pointAQUAE Holdings agreement for climate finance infrastructure was signed by MindWave in September 2026
- Moderate pointFlash Sports & Media Holdings agreement for sports media infrastructure was signed by MindWave in September 2026
- Moderate point. Forward-looking: it has not happened yet and may not happen.Bermuda joint venture with Skalup Capital gives MindWave a 75% stake in a venture to establish an insurance and technology business
3 minor points
- Minor pointSoftware development and deployment services generated $2.48 million from two enterprise customers in the third quarter
- Minor pointNine-month revenue was $3.2 million through September 30, 2026
- Minor point. Forward-looking: it has not happened yet and may not happen.Recurring revenue is a company goal for contracted project work
Negative
- Major pointSubstantial doubt about continued operations remains, and Apimeds is pursuing capital raising and refinancing alternatives
- Major point. Forward-looking: it has not happened yet and may not happen.Senior secured convertible note with $10.5 million in outstanding principal matures December 8, 2026 2.9× market cap
- Major pointNine-month net loss was $21.6 million, or $12.89 per share, reflecting transition-related costs earlier in 2026
- Moderate pointDigital assets accounted for $142.4 million, or 93% of total assets, at September 30, 2026
- Minor pointCash was $17,912 at September 30, 2026, with a separate $8.0 million in restricted cash
4 minor points
- Minor pointGeneral and administrative expenses were $12.0 million for the nine months and $0.8 million for the third quarter
- Minor pointRelated-party customer was one of two enterprise customers that received software development and deployment services in the third quarter
- Minor point. Forward-looking: it has not happened yet and may not happen.Bermuda joint venture is subject to licensing by the Bermuda Monetary Authority
- Minor pointThird-quarter cost of revenue was $54,300
News Explained
MindWave’s Bermuda joint-venture stake depends on licensing, while the subsidiary’s October financing has no stated form or terms.
MindWave, Apimeds’ wholly owned subsidiary, signed technology-services agreements with AQUAE Holdings and Flash Sports & Media Holdings in September 2026.
It also signed a two-year master agreement with BlockAssure on
MindWave also entered a Bermuda insurance-and-technology joint venture with Skalup Capital, with MindWave holding
Separately, the company reports that its subsidiary received
Key Figures
- Quarterly revenue
- $2.89 million
- Third quarter 2026; compared with no revenue in the third quarter of 2025
- Software services revenue
- $2.48 million
- Delivered to two enterprise customers, one of which is a related party
- Operating income
- $2.0 million
- Third quarter 2026
- Net income
- $33.6 million
- Third quarter 2026; includes a $25.26 million unrealized gain on digital assets
- Nine-month net loss
- $21.6 million
- Nine months ended September 30, 2026
- Cash and restricted cash
- $17,912 cash; $8.0 million restricted cash
- At September 30, 2026
- Digital assets
- $142.4 million, or 93%
- Share of total assets at September 30, 2026
- Senior secured convertible note
- $10.5 million outstanding principal
- Matures December 8, 2026
Key Terms
discontinued operations financial
restricted cash financial
convertible note financial
going concern financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Quarterly revenue of
MATAWAN, N.J., Nov. 18, 2026 (GLOBE NEWSWIRE) -- via IBN – Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), today reported financial results for the third quarter ended September 30, 2026, as filed in its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission.
Third Quarter 2026 Highlights
- Revenue of
$2.89 million , compared with no revenue in the third quarter of 2025, the Company’s first full quarter of revenue from its technology business. $2.48 million from software development and deployment services delivered to two enterprise customers, one of which is a related party.- Operating income of
$2.0 million for the quarter, on cost of revenue of$54,300 and general and administrative expenses of$0.8 million . - Net income of
$33.6 million , or$19.13 per basic share and$7.68 per diluted share, which includes a$25.26 million unrealized gain on digital assets. - Total assets of
$153.5 million and shareholders’ equity of$140.5 million at September 30, 2026. - Business transition completed with the disposal of the Company’s former biopharmaceutical subsidiary on July 14, 2026, now reported as discontinued operations.
Recent Business Developments
- Enterprise client agreements: Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) operates through its wholly owned subsidiary MindWave Innovations Inc. (“MindWave”). MindWave signed technology services agreements with AQUAE Holdings for climate finance infrastructure and Flash Sports & Media Holdings for sports media infrastructure in September 2026, followed by a two-year master agreement with Delaware-based BlockAssure Inc. for insurance infrastructure on October 4, 2026.
- Bermuda insurance joint venture: MindWave entered into a joint venture with Singapore-based Skalup Capital to establish an insurance and technology business in Bermuda, with MindWave holding
75% , subject to licensing by the Bermuda Monetary Authority. - Leadership: Eric Sherb was appointed Chief Financial Officer effective October 1, 2026.
- Financing: The Company’s subsidiary received
$750,000 in financing in October 2026.
“The third quarter marks a turning point for the Company, with our first meaningful revenue from technology services and operating income for the quarter,” said Dr. Vin Menon, Chief Executive Officer of MindWave.
“We have signed enterprise agreements across climate finance, sports media and insurance, all running on the same MindChain infrastructure. Our focus now is delivering those projects on schedule, converting contracted work into recurring revenue and strengthening our balance sheet.”
Nine-Month Results
For the nine months ended September 30, 2026, revenue was
Balance Sheet and Liquidity
On September 30, 2026, the Company held cash of
About Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) operates through its wholly owned subsidiary, MindWave, which develops enterprise technology infrastructure and builds and operates dedicated networks for clients in climate finance, sports media, insurance and financial services.
About MindWave Innovations Inc.
MindWave develops enterprise blockchain infrastructure, including the MindChain network, and institutional platforms for regulated financial services, real-world asset digitization and enterprise applications. For more information, visit https://www.mindwaveinnovations.com/
Forward-Looking Statements
Certain statements and information in this earnings release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our expectations, beliefs, plans, financial prospects and guidance; financial or performance estimates and expectations (including estimated or expected revenues, earnings, operating income, timing of expenses, tax rates, acquisition amortization and cash flow) and expected drivers; impact of future efficiencies and cost savings; future capital allocation, including investments, capital expenditures and share repurchases, and expected drivers; strategies, priorities and opportunities for growth, including plans for, the delivery of client projects, future revenue, the Bermuda joint venture, capital raising and refinancing, and the Company’s business strategy. These statements are based on current expectations and are subject to risks and uncertainties, including the Company’s ability to continue as a going concern, to refinance or repay its senior secured note, to collect amounts due from customers, to regain and maintain compliance with NYSE American listing standards, and the volatility of the value of its digital assets, as well as the risks described in the Company’s filings with the SEC. Any information that is not historical in nature is subject to change. These statements are made on the basis of management’’ views and assumptions regarding future events and business performance as of the time the statements are made. The Company undertakes no obligation to update these statements except as required by law.
Actual results may differ materially. Such differences may result from actions taken by the Company, including restructuring or strategic initiatives (including capital investments, asset acquisitions or dispositions, new or expanded business lines or cessation of certain operations), our execution of our business plans, our ability to quickly execute on cost rationalization while preserving revenue, the discovery of additional information or other business decisions, as well as from developments beyond the Company’s control, including:
- the occurrence of subsequent events;
- deterioration in domestic and global economic conditions or failure of conditions to improve as anticipated;
- international, including tariffs and other trade policies, political or military developments;
- regulatory and legal developments; and
- technological developments.
Additional factors are set forth in the Company’s most recent Annual Report on Form 10-K, including under the captions “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and “Business,” subsequent quarterly reports on Form 10-Q, including under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and subsequent filings with the Securities and Exchange Commission.
Media and Investor Relations MindWave Innovations Inc. contact@mindwaveinnovations.com
Corporate Communications:
IBN.Ai
Austin, Texas
512.354.7000 Office
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.